An independent review by Professor Cathie Sudlow, Uniting the UK’s Health Data: A Huge Opportunity for Society, highlights the urgent need to tackle inefficiencies in the UK’s health data systems. Published on 8 November 2024, the review outlines how outdated processes are preventing the safe and secure use of health data to improve care, drive research, and benefit society.
Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.
The recently published ‘Advancing Clinical Trials’ report puts forward equality, diversity and inclusion (EDI) in clinical trials as central to the future of in the UK’s life sciences industry.
The UK Government has published its Medical Technology Strategy policy document, designed to ensure that the health and social care system can access safe, effective and innovative medical technologies.
For companies new to the UK, the UK life science sector may seem daunting. This actionable take away summary highlights four key areas to be aware of when first entering this sector. Download the full summary.
